Lifecore Biomedical, Inc. De (LFCR) Common Equity (2011 - 2025)

Lifecore Biomedical's Common Equity history runs 15 years deep, the most recent figure standing at $1.3 million for Q2 2025.

• In Q2 2025, Common Equity fell 88.19% year-over-year to $1.3 million; the TTM figure through May 2025 stood at $1.3 million (down 88.19% YoY), while the FY2025 annual figure was $1.3 million, down 88.19% from the prior year.
• Common Equity was $1.3 million for Q2 2025 at Lifecore Biomedical, down from $2.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $202.2 million in Q1 2021 to a low of -$13.6 million in Q3 2023.
• Historically, Common Equity has averaged $66.4 million across 5 years, with a median of $26.4 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Common Equity tumbled 117.41% in 2023, then surged 987.19% in 2024.
• A 5-year view of Common Equity shows it stood at $155.4 million in 2021, then plunged by 54.23% to $71.1 million in 2022, then plunged by 98.0% to $1.4 million in 2023, then soared by 987.19% to $15.4 million in 2024, then plunged by 91.35% to $1.3 million in 2025.
• The last three Common Equity figures came in at $1.3 million (Q2 2025), $2.2 million (Q1 2025), and $15.4 million (Q4 2024), per Business Quant data.